Jun 13, 2024 Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
Apr 9, 2024 Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
Mar 27, 2024 Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Mar 25, 2024 Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
Mar 20, 2024 Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024